SIMILAR PATTERN OF AMINO ACIDS MAPPED TO '5f89'

List of Similar Pattern of Amino Acids

Hit pattern: 3D amino acid arrangements similar to known drug binding site
Query pattern: Residues from known binding site for annotated drug that match the hit pattern

(Click on the DrReposER ID to view details on interfaces and similar patterns of amino acids)
(Click on the view link on the last column to view superposed patterns of amino acids)

Filter list by:

	DrReposER ID / Desc.	Hit PDBID	Hit Macromolecule	Res. Matches	Interface	HETATM	RMSD	Dali Z-score	Seq. Identity (%)
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	1T6Z_A_RBFA296_1 (RIBOFLAVIN KINASE/FMN ADENYLYLTRANSFERASE)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	5 / 11	THR L 162 VAL L 196 VAL L 145 GLU L 204 LYS L 205	None	1.48A	1t6zA-5f89L: undetectable	1t6zA-5f89L: 20.06
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	2OLD_B_IPHB2001_0 (BENCE JONES KWR PROTEIN - IMMUNOGLOBULIN LIGHT CHAIN)	5f89	CAP248-2B HEAVY CHAIN CAP248-2B LIGHT CHAIN (Homo sapiens; Homo sapiens)	4 / 7	TYR L 36 PRO L 44 TYR L 87 TYR H 91	None	0.74A	2oldA-5f89L: 6.1 2oldB-5f89L: 24.8	2oldA-5f89L: 84.89 2oldB-5f89L: 84.89
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3D4S_A_TIMA401_2 (BETA-2 ADRENERGIC RECEPTOR/T4-LYSOZYME CHIMERA)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	3 / 3	THR L 115 SER L 138 PHE L 119	None	0.80A	3d4sA-5f89L: undetectable	3d4sA-5f89L: 18.05
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	3NBR_A_ASDA129_1 (STEROID DELTA-ISOMERASE)	5f89	CAP248-2B HEAVY CHAIN CAP248-2B LIGHT CHAIN (Homo sapiens)	5 / 12	PHE H 166 VAL L 196 VAL L 145 PRO L 114 PHE L 140	None	1.44A	3nbrA-5f89H: undetectable	3nbrA-5f89H: 19.31
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4E0F_A_RBFA301_1 (RIBOFLAVIN SYNTHASE SUBUNIT ALPHA)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	5 / 11	SER L 100 VAL L 97 LEU L 4 THR L 5 THR L 92	None	1.24A	4e0fA-5f89L: undetectable	4e0fA-5f89L: 22.61
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4HXY_B_ACAB502_1 (PLM1)	5f89	CAP248-2B HEAVY CHAIN CAP248-2B LIGHT CHAIN (Homo sapiens)	4 / 7	VAL H 169 SER L 180 GLN H 171 LEU H 141	None	1.08A	4hxyB-5f89H: undetectable	4hxyB-5f89H: 17.93
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvnH-5f89H: undetectable 4qvnI-5f89H: undetectable	4qvnH-5f89H: 18.60 4qvnI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVN_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 10	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvnV-5f89H: undetectable 4qvnW-5f89H: undetectable	4qvnV-5f89H: 18.60 4qvnW-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.82A	4qvpH-5f89H: undetectable 4qvpI-5f89H: undetectable	4qvpH-5f89H: 18.60 4qvpI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVP_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.82A	4qvpV-5f89H: undetectable 4qvpW-5f89H: undetectable	4qvpV-5f89H: 18.60 4qvpW-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvqH-5f89H: undetectable 4qvqI-5f89H: undetectable	4qvqH-5f89H: 18.60 4qvqI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVQ_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.83A	4qvqV-5f89H: undetectable 4qvqW-5f89H: undetectable	4qvqV-5f89H: 18.60 4qvqW-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.85A	4qvvH-5f89H: undetectable	4qvvH-5f89H: 18.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVV_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvvV-5f89H: undetectable	4qvvV-5f89H: 18.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvyH-5f89H: undetectable	4qvyH-5f89H: 18.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QVY_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qvyV-5f89H: undetectable 4qvyW-5f89H: undetectable	4qvyV-5f89H: 18.60 4qvyW-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qw0H-5f89H: undetectable 4qw0I-5f89H: undetectable	4qw0H-5f89H: 18.60 4qw0I-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW0_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	4qw0V-5f89H: undetectable 4qw0W-5f89H: undetectable	4qw0V-5f89H: 18.60 4qw0W-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	4qw1H-5f89H: undetectable 4qw1I-5f89H: undetectable	4qw1H-5f89H: 18.60 4qw1I-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QW1_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	4qw1V-5f89H: undetectable 4qw1W-5f89H: undetectable	4qw1V-5f89H: 18.60 4qw1W-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QWU_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	4qwuH-5f89H: undetectable 4qwuI-5f89H: undetectable	4qwuH-5f89H: 18.60 4qwuI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	4QWU_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	4qwuV-5f89H: undetectable 4qwuW-5f89H: undetectable	4qwuV-5f89H: 18.60 4qwuW-5f89H: 22.22
Available target for annotated drug, i.e. matched protein structure has more than 30% sequence identity to known drug target.	5ACL_A_SASA1111_1 (MCG)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	5 / 7	TYR L 32 SER L 34 TYR L 36 TYR L 49 PRO L 55	None	0.73A	5aclA-5f89L: 21.4	5aclA-5f89L: 71.43
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5BXN_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.86A	5bxnH-5f89H: undetectable 5bxnI-5f89H: undetectable	5bxnH-5f89H: 20.37 5bxnI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5CZ7_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	5cz7V-5f89H: undetectable 5cz7W-5f89H: undetectable	5cz7V-5f89H: 18.60 5cz7W-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5D0X_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.83A	5d0xV-5f89H: undetectable	5d0xV-5f89H: 18.60
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ESL_A_1YNA701_2 (LANOSTEROL 14-ALPHA DEMETHYLASE)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	4 / 5	ALA L 174 TYR L 173 PRO L 40 GLY L 99	None	0.99A	5eslA-5f89L: undetectable	5eslA-5f89L: 17.92
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.81A	5l5fH-5f89H: undetectable 5l5fI-5f89H: undetectable	5l5fH-5f89H: 18.60 5l5fI-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L5F_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.81A	5l5fV-5f89H: undetectable 5l5fW-5f89H: undetectable	5l5fV-5f89H: 18.60 5l5fW-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L66_H_BO2H301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.85A	5l66H-5f89H: undetectable 5l66I-5f89H: undetectable	5l66H-5f89H: 18.60 5l66I-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5L66_V_BO2V301_1 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.84A	5l66V-5f89H: undetectable 5l66W-5f89H: undetectable	5l66V-5f89H: 18.60 5l66W-5f89H: 22.22
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5UBB_A_SAMA301_0 (ALPHA N-TERMINAL PROTEIN METHYLTRANSFERASE 1B)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	MET H 108 SER H 177 LEU H 178 VAL H 150 HIS H 200	None	1.27A	5ubbA-5f89H: undetectable	5ubbA-5f89H: 19.44
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	5ZW2_A_ACTA511_0 (L-PROLYL-[PEPTIDYL-C ARRIER PROTEIN] DEHYDROGENASE)	5f89	CAP248-2B LIGHT CHAIN (Homo sapiens)	3 / 3	ARG L 54 ILE L 58 SER L 59	None	0.81A	5zw2A-5f89L: undetectable	5zw2A-5f89L: 19.70
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6AWP_A_FVXA701_1 (SODIUM-DEPENDENT SEROTONIN TRANSPORTER)	5f89	CAP248-2B HEAVY CHAIN CAP248-2B LIGHT CHAIN (Homo sapiens)	5 / 9	SER L 177 SER H 179 SER H 180 GLY H 139 THR L 115	None	1.39A	6awpA-5f89L: undetectable	6awpA-5f89L: 17.57
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6B58_A_ACTA606_0 (FUMARATE REDUCTASE FLAVOPROTEIN SUBUNIT)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	4 / 5	GLU H 148 PHE H 146 HIS H 200 THR H 110	None	1.20A	6b58A-5f89H: undetectable	6b58A-5f89H: 15.83
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_H_BO2H301_0 (PROTEASOME SUBUNIT BETA TYPE-2 PROTEASOME SUBUNIT BETA TYPE-3)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 12	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.97A	6hwdH-5f89H: undetectable 6hwdI-5f89H: undetectable	6hwdH-5f89H: 19.31 6hwdI-5f89H: 15.35
Potential target for repurposing, i.e. matched protein structure has less than 30% sequence identity to known drug target, and may potentially interact with the same drug molecule based on local structural similarity of binding site.	6HWD_V_BO2V301_0 (PROTEASOME SUBUNIT BETA TYPE-2)	5f89	CAP248-2B HEAVY CHAIN (Homo sapiens)	5 / 11	SER H 188 GLY H 134 THR H 135 ALA H 136 THR H 131	None	0.97A	6hwdV-5f89H: undetectable	6hwdV-5f89H: 19.31

[["DrReposER ID","Desc.","Hit PDB","Hit molecule","Hit organism","Res. no.","Interface","HETATM","RMSD","Z-score","Seq ID"],["1T6Z_A_RBFA296_1","RIBOFLAVIN KINASE\/FMN ADENYLYLTRANSFERASE","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",5,"THR L 162;VAL L 196;VAL L 145;GLU L 204;LYS L 205","None","1.48A","1t6zA-5f89L:undetectable","1t6zA-5f89L:20.06"],["2OLD_B_IPHB2001_0","BENCE JONES KWR PROTEIN - IMMUNOGLOBULIN LIGHT CHAIN","5f89","CAP248-2B HEAVY CHAIN;CAP248-2B LIGHT CHAIN","Homo sapiens;Homo sapiens",4,"TYR L  36;PRO L  44;TYR L  87;TYR H  91","None","0.74A","2oldA-5f89L:6.1;2oldB-5f89L:24.8","2oldA-5f89L:84.89;2oldB-5f89L:84.89"],["3D4S_A_TIMA401_2","BETA-2 ADRENERGIC RECEPTOR\/T4-LYSOZYME CHIMERA","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",3,"THR L 115;SER L 138;PHE L 119","None","0.80A","3d4sA-5f89L:undetectable","3d4sA-5f89L:18.05"],["3NBR_A_ASDA129_1","STEROID DELTA-ISOMERASE","5f89","CAP248-2B HEAVY CHAIN;CAP248-2B LIGHT CHAIN","Homo sapiens",5,"PHE H 166;VAL L 196;VAL L 145;PRO L 114;PHE L 140","None","1.44A","3nbrA-5f89H:undetectable","3nbrA-5f89H:19.31"],["4E0F_A_RBFA301_1","RIBOFLAVIN SYNTHASE SUBUNIT ALPHA","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",5,"SER L 100;VAL L  97;LEU L   4;THR L   5;THR L  92","None","1.24A","4e0fA-5f89L:undetectable","4e0fA-5f89L:22.61"],["4HXY_B_ACAB502_1","PLM1","5f89","CAP248-2B HEAVY CHAIN;CAP248-2B LIGHT CHAIN","Homo sapiens",4,"VAL H 169;SER L 180;GLN H 171;LEU H 141","None","1.08A","4hxyB-5f89H:undetectable","4hxyB-5f89H:17.93"],["4QVN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvnH-5f89H:undetectable;4qvnI-5f89H:undetectable","4qvnH-5f89H:18.60;4qvnI-5f89H:22.22"],["4QVN_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvnV-5f89H:undetectable;4qvnW-5f89H:undetectable","4qvnV-5f89H:18.60;4qvnW-5f89H:22.22"],["4QVP_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.82A","4qvpH-5f89H:undetectable;4qvpI-5f89H:undetectable","4qvpH-5f89H:18.60;4qvpI-5f89H:22.22"],["4QVP_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.82A","4qvpV-5f89H:undetectable;4qvpW-5f89H:undetectable","4qvpV-5f89H:18.60;4qvpW-5f89H:22.22"],["4QVQ_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvqH-5f89H:undetectable;4qvqI-5f89H:undetectable","4qvqH-5f89H:18.60;4qvqI-5f89H:22.22"],["4QVQ_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.83A","4qvqV-5f89H:undetectable;4qvqW-5f89H:undetectable","4qvqV-5f89H:18.60;4qvqW-5f89H:22.22"],["4QVV_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.85A","4qvvH-5f89H:undetectable","4qvvH-5f89H:18.60"],["4QVV_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvvV-5f89H:undetectable","4qvvV-5f89H:18.60"],["4QVY_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvyH-5f89H:undetectable","4qvyH-5f89H:18.60"],["4QVY_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qvyV-5f89H:undetectable;4qvyW-5f89H:undetectable","4qvyV-5f89H:18.60;4qvyW-5f89H:22.22"],["4QW0_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qw0H-5f89H:undetectable;4qw0I-5f89H:undetectable","4qw0H-5f89H:18.60;4qw0I-5f89H:22.22"],["4QW0_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","4qw0V-5f89H:undetectable;4qw0W-5f89H:undetectable","4qw0V-5f89H:18.60;4qw0W-5f89H:22.22"],["4QW1_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","4qw1H-5f89H:undetectable;4qw1I-5f89H:undetectable","4qw1H-5f89H:18.60;4qw1I-5f89H:22.22"],["4QW1_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","4qw1V-5f89H:undetectable;4qw1W-5f89H:undetectable","4qw1V-5f89H:18.60;4qw1W-5f89H:22.22"],["4QWU_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","4qwuH-5f89H:undetectable;4qwuI-5f89H:undetectable","4qwuH-5f89H:18.60;4qwuI-5f89H:22.22"],["4QWU_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","4qwuV-5f89H:undetectable;4qwuW-5f89H:undetectable","4qwuV-5f89H:18.60;4qwuW-5f89H:22.22"],["5ACL_A_SASA1111_1","MCG","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",5,"TYR L  32;SER L  34;TYR L  36;TYR L  49;PRO L  55","None","0.73A","5aclA-5f89L:21.4","5aclA-5f89L:71.43"],["5BXN_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.86A","5bxnH-5f89H:undetectable;5bxnI-5f89H:undetectable","5bxnH-5f89H:20.37;5bxnI-5f89H:22.22"],["5CZ7_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","5cz7V-5f89H:undetectable;5cz7W-5f89H:undetectable","5cz7V-5f89H:18.60;5cz7W-5f89H:22.22"],["5D0X_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.83A","5d0xV-5f89H:undetectable","5d0xV-5f89H:18.60"],["5ESL_A_1YNA701_2","LANOSTEROL 14-ALPHA DEMETHYLASE","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",4,"ALA L 174;TYR L 173;PRO L  40;GLY L  99","None","0.99A","5eslA-5f89L:undetectable","5eslA-5f89L:17.92"],["5L5F_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.81A","5l5fH-5f89H:undetectable;5l5fI-5f89H:undetectable","5l5fH-5f89H:18.60;5l5fI-5f89H:22.22"],["5L5F_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.81A","5l5fV-5f89H:undetectable;5l5fW-5f89H:undetectable","5l5fV-5f89H:18.60;5l5fW-5f89H:22.22"],["5L66_H_BO2H301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.85A","5l66H-5f89H:undetectable;5l66I-5f89H:undetectable","5l66H-5f89H:18.60;5l66I-5f89H:22.22"],["5L66_V_BO2V301_1","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.84A","5l66V-5f89H:undetectable;5l66W-5f89H:undetectable","5l66V-5f89H:18.60;5l66W-5f89H:22.22"],["5UBB_A_SAMA301_0","ALPHA N-TERMINAL PROTEIN METHYLTRANSFERASE 1B","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"MET H 108;SER H 177;LEU H 178;VAL H 150;HIS H 200","None","1.27A","5ubbA-5f89H:undetectable","5ubbA-5f89H:19.44"],["5ZW2_A_ACTA511_0","L-PROLYL-[PEPTIDYL-CARRIER PROTEIN] DEHYDROGENASE","5f89","CAP248-2B LIGHT CHAIN","Homo sapiens",3,"ARG L  54;ILE L  58;SER L  59","None","0.81A","5zw2A-5f89L:undetectable","5zw2A-5f89L:19.70"],["6AWP_A_FVXA701_1","SODIUM-DEPENDENT SEROTONIN TRANSPORTER","5f89","CAP248-2B HEAVY CHAIN;CAP248-2B LIGHT CHAIN","Homo sapiens",5,"SER L 177;SER H 179;SER H 180;GLY H 139;THR L 115","None","1.39A","6awpA-5f89L:undetectable","6awpA-5f89L:17.57"],["6B58_A_ACTA606_0","FUMARATE REDUCTASE FLAVOPROTEIN SUBUNIT","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",4,"GLU H 148;PHE H 146;HIS H 200;THR H 110","None","1.20A","6b58A-5f89H:undetectable","6b58A-5f89H:15.83"],["6HWD_H_BO2H301_0","PROTEASOME SUBUNIT BETA TYPE-2;PROTEASOME SUBUNIT BETA TYPE-3","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.97A","6hwdH-5f89H:undetectable;6hwdI-5f89H:undetectable","6hwdH-5f89H:19.31;6hwdI-5f89H:15.35"],["6HWD_V_BO2V301_0","PROTEASOME SUBUNIT BETA TYPE-2","5f89","CAP248-2B HEAVY CHAIN","Homo sapiens",5,"SER H 188;GLY H 134;THR H 135;ALA H 136;THR H 131","None","0.97A","6hwdV-5f89H:undetectable","6hwdV-5f89H:19.31"]]